211311-95-4

LY404187 is a benzothiadiazide positive allosteric modulator of AMPA receptors. It increases glutamate-induced activation of GluR1_i, -2_i, -2_o, -3_i, and -4_i subunit-containing AMPA receptors with EC₅₀ values of 5.65, 0.15, 1.44, 1.66, and 0.21 μM, respectively, in a calcium influx assay. LY404187 is selective for these AMPA receptors over GluR6 subunit-containing kainate receptors at 10 μM. LY404187 increases currents induced by glutamate and AMPA in rat prefrontal cortex pyramidal neurons (EC₅₀s = 1.3 and 1.2 μM, respectively) but not in AMPA-stimulated primary rat embryonic hippocampal or primary cerebellar Purkinje neurons. LY404187 prevents decreases in the number of dopaminergic neurons in the substantia nigra induced by MPTP and 6-OHDA in mouse and rat, respectively, models of Parkinson’s disease when administered at a dose of 0.5 mg/kg per day.

LY 404187 is a novel positive allosteric modulator of AMPA receptors.

Store at +4°C

[1] P MIU . Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro[J]. Neuropharmacology, 2001, 40 8: Pages 976-983. DOI: 10.1016/s0028-3908(01)00027-2
[2] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[3] M GATES  D B  A Ogden. Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro[J]. Neuropharmacology, 2001, 40 8: Pages 984-991. DOI: 10.1016/s0028-3908(01)00040-5
[4] MICHAEL J O’NEILL . Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson’s disease[J]. European journal of pharmacology, 2004, 486 2: Pages 163-174. DOI: 10.1016/j.ejphar.2003.12.023